We unlocked almost $180 billion of value.

Took this company that was a conglomerate and we turned it into four companies.

We had these other businesses, but it was never really the core of kind of who we are.

We were misallocating capital.

Spitting off companies sounds easy in retrospect.

Actually, spitting off three public companies is a massive, massive undertaking.

You can rewind a disease or completely, in some cases, almost create a functional cure for patients.

One of our sentinel patients was an individual in bed all the time, receives our cell therapy.

Six months later, no sign of disease.

I mean, this is extraordinary.

Cell therapy is an immunology, alongside immune reset by mean, this is extraordinary. Cell therapies and immunology,

alongside immune reset by specific, tri-specific.

That is going to be a whole renaissance for cell therapy.

When Vassant Narasimhan became CEO of Novartis in 2018,

he inherited a conglomerate, consumer health, animal health, vaccines, generics, devices. Over six years,

he spun off three public companies and unlocked almost $180 billion of value. Today, Novartis

is focused on four disease areas and three platform technologies, cell and gene therapies,

RNA medicines, and radiolagin therapies. One of their gene therapies, Z medicines, and radioligan therapies.

One of their gene therapies, Zolgensma, treats children with spinal muscular atrophy,

a disease that would otherwise be fatal by age two.

It costs over $2 million, and it's reimbursed in 48 countries.

Basin started his career doing public health work on tuberculosis in Peru with Paul Farmer and Jim Kim.

...